持久性左心室辅助装置在循环死亡后心脏移植中的应用
本研究基于UNOS注册数据分析2019年1月1日至2023年3月31日成人孤立性循环死亡后(DCD)心脏移植受者,按是否使用持久性左心室辅助装置(LVAD)作为桥接分层。共纳入703例,其中219例(31.2%)使用持久性LVAD桥接。使用持久性LVAD的DCD心脏移植受者1年生存率显著低于未使用者(88.4% vs. 93.6%,p=0.017),但临床状态和装置类型显著影响预后,且持久性LVAD受者DCD与DBD移植的1年生存率相当(88.4% vs. 89.0%,p=0.763)。
要点
- DCD心脏移植中持久性LVAD桥接受者1年生存率显著低于未桥接受者。
- 状态4受者1年生存率优于状态2和3受者,装置类型影响预后。
- 持久性LVAD受者DCD与DBD心脏移植的1年生存率相当。
核心结论
- 使用持久性LVAD桥接的DCD心脏移植受者早期移植后生存率低于未使用持久性LVAD者。
- 临床状态和装置类型显著影响该人群的移植后结局。
- 持久性LVAD候选者可安全接受DCD心脏移植,早期生存率与DBD心脏移植相当。
研究设计与样本
- 回顾性队列研究,查询UNOS注册数据库,分析2019年1月1日至2023年3月31日成人孤立性DCD心脏移植受者。
- 按是否使用持久性LVAD作为移植桥接进行分层,主要结局为移植后1年生存率。
- 亚组分析评估移植状态、装置类型和供者类型对1年生存率的影响。
主要发现
- 共纳入703例受者,其中219例(31.2%)使用持久性LVAD桥接。
- 持久性LVAD组1年生存率显著低于非持久性LVAD组(88.4% vs. 93.6%,p=0.017)。
- 在持久性LVAD桥接受者中,状态4受者1年生存率显著优于状态2和3受者,与非持久性LVAD组相似。
- 使用HeartMate II和HeartMate 3的受者生存率优于使用HeartWare HVAD者,与非持久性LVAD组相似。
- 持久性LVAD受者中DCD与DBD心脏移植的1年生存率相当(88.4% vs. 89.0%,p=0.763)。
临床怎么用
- 持久性LVAD患者可考虑DCD心脏移植,但需知晓早期生存率低于未使用持久性LVAD者。
- 选择DCD心脏移植时,应评估临床状态(如状态4可能预后更优)和LVAD装置类型。
- 持久性LVAD受者接受DCD心脏移植的早期生存率与DBD心脏移植相当,可作为供心来源的可行选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluates outcomes following donation after circulatory death (DCD) heart transplantation in recipients with a durable left ventricular assist device (LVAD). METHODS: The UNOS registry was queried to analyze adult recipients of isolated DCD heart transplantation between 1/1/2019-3/31/2023. The recipients were stratified by durable LVAD use as a bridge to transplantation. The primary outcome was 1-year post-transplant survival. Sub-group analyses were conducted to evaluate the effects of transplant status, device type, and donor type on 1-year survival. RESULTS: A total of 703 recipients were included, of which 219 (31.2%) recipients were bridged with a durable LVAD. The recipients of DCD hearts with durable LVADs had significantly lower 1-year post-transplant survival compared to those without durable LVADs (88.4% vs. 93.6%, p=0.017). Among the recipients bridged with durable LVADs, status 4 recipients had significantly improved 1-year survival compared to statuses 2 and 3 recipients, similar to those without durable LVADs. Furthermore, the recipients with HeartMate II and HeartMate 3 had improved survival compared to those with the HeartWare HVAD, similar to those without durable LVADs. Lastly, the DCD and DBD recipients with durable LVADs had comparable 1-year survival (88.4% vs. 89.0%, p=0.763). CONCLUSIONS: Recipients of DCD hearts bridged to transplantation with a durable LVAD exhibit reduced early post-transplant survival compared to those without a durable LVAD. However, clinical acuity and device type significantly influence post-transplant outcomes in this vulnerable population. Despite this, candidates with a durable LVAD can safely undergo DCD heart transplantation, achieving early post-transplant survival comparable to those of DBD heart transplantation.
引用
- Hong Y, Nasim U, Iyanna N, et al. Durable left ventricular assist device in donation after circulatory death heart transplantation. J Heart Lung Transplant. 2025. PMID: 39947501. doi:10.1016/j.healun.2025.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。